替非珠單抗
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | 聚集因子A |
| 臨床資料 | |
| 商品名 | Aurexis |
| 其他名稱 | 特非珠單抗、INH-H 2002 |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 521079-87-8  |
| ChemSpider | |
| UNII | |
| KEGG | |
| 化學資訊 | |
| 化學式 | C6548H10122N1730O2034S44 |
| 摩爾質量 | 147,035.72 g·mol−1 |
替非珠單抗（INN：Tefibazumab）是一種人源化單株抗體，用於治療金黃色葡萄球菌的嚴重感染。可能的適應症包括治療患有囊性纖維化的2a期患者的金黃色葡萄球菌[1]和耐甲氧西林金黃色葡萄球菌。[2]該藥物由Inhibitex開發的。[3]
參見
[編輯]參考資料
[編輯]- ^ Clinical trial number NCT00198289 for "Aurexis in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs" at ClinicalTrials.gov
- ^ Pan A, Lorenzotti S, Zoncada A. Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection. Recent Patents on Anti-Infective Drug Discovery. January 2008, 3 (1): 10–33. PMID 18221183. doi:10.2174/157489108783413173.
- ^ John JF. Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection. Current Opinion in Molecular Therapeutics. October 2006, 8 (5): 455–60. PMID 17078388.